| Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules | 08/21 06:00 | globenewswire.com |
| Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension | 07/09 08:00 | globenewswire.com |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH | 06/01 12:00 | accesswire.com |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH | 05/30 19:20 | prnewswire.com |
| Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | 05/29 16:45 | globenewswire.com |
| Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | 05/28 08:00 | globenewswire.com |
| Reviva to Participate in the BIO International Convention | 05/21 08:00 | globenewswire.com |
| Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia | 05/15 08:00 | globenewswire.com |